Theralase(R) Closes $1.3 M Non-Brokered Private Placement

Executive Summary

• Theralase® Technologies Inc. closed a non‑brokered private placement of 7,850,882 units at $0.17 CAD per unit, generating approximately $1.33 million CAD in gross proceeds.
• Each unit includes one common share and one warrant to purchase an additional share at $0.21 CAD for five years; a finder fee of $31,658 CAD was paid partly in cash and partly via share issuance.
• Proceeds will fund the Phase II NMIBC clinical study, working capital, and general corporate purposes.

Key Details

• Units Issued: 7,850,882 units at $0.17 CAD per unit.
• Gross Proceeds: Approximately $1,334,650 CAD.
• Unit Composition: 1 common share + 1 warrant (exercise price $0.21 CAD, five‑year term).
• Finder Compensation: $31,658 CAD total – $15,470 CAD paid in cash and $16,188 CAD paid via issuance of 95,221 common shares; plus 186,221 non‑transferable finder warrants (exercise price $0.21 CAD, five‑year term).
• Use of Proceeds: Advance Phase II Non‑Muscle Invasive Bladder Cancer (NMIBC) clinical study, working capital, and general corporate purposes.
• Holding Period: Securities subject to a four‑month‑plus‑one‑day hold period expiring 2026‑04‑24 under Canadian securities laws.
• Closing Conditions: Subject to final acceptance by the TSX Venture Exchange.

Notable Quotes

(No direct quotes were included in the release.)